b83a1cf6-50a6-44fa-834d-8b3df88149fa
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.360
- COAGULATION+0.340
- OXIDATIVE_PHOSPHORYLATION+0.320
- P53_PATHWAY+0.300
- PANCREAS_BETA_CELLS+0.300
- IL6_JAK_STAT3_SIGNALING+0.280
- ESTROGEN_RESPONSE_LATE+0.270
- APICAL_JUNCTION+0.260
- APICAL_SURFACE+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.380
- G2M_CHECKPOINT-0.310
- UV_RESPONSE_DN-0.300
- ANDROGEN_RESPONSE-0.290
- MITOTIC_SPINDLE-0.230
- E2F_TARGETS-0.220
- SPERMATOGENESIS-0.110
- MYC_TARGETS_V1-0.080
- MTORC1_SIGNALING-0.050
- HEME_METABOLISM-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.873 |
| 2 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.866 |
| 3 | 26251cd8-7e90-46bb-a025-1328d83c83ee | — | — | 0.861 |
| 4 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.835 |
| 5 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.831 |
| 6 | d6b7de60-321d-4f6d-82e7-3d5e9598462c | — | — | 0.820 |
| 7 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.816 |
| 8 | a97448d4-418a-4e9c-bd75-c4d217c20c89 | — | — | 0.804 |
| 9 | MNG1110 | — | — | 0.803 |
| 10 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |